NovaBay Pharmaceuticals (NBY)
(Delayed Data from AMEX)
$1.94 USD
-0.22 (-10.19%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $2.04 +0.10 (5.15%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Income Statements
Fiscal Year end for NovaBay Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 15 | 14 | 8 | 10 | 7 |
Cost Of Goods | 7 | 7 | 3 | 4 | 2 |
Gross Profit | 8 | 8 | 6 | 6 | 5 |
Selling & Adminstrative & Depr. & Amort Expenses | 15 | 22 | 15 | 12 | 14 |
Income After Depreciation & Amortization | -8 | -14 | -9 | -6 | -9 |
Non-Operating Income | -2 | 4 | 3 | -5 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -10 | -11 | -6 | -11 | -10 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -10 | -11 | -6 | -11 | -10 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -10 | -11 | -6 | -11 | -10 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -3 | -7 | -9 | -6 | -9 |
Depreciation & Amortization (Cash Flow) | 4 | 7 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -8 | -14 | -9 | -6 | -9 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.12 | 0.05 | 0.04 | 0.03 | 0.02 |
Diluted EPS Before Non-Recurring Items | -117.13 | -353.15 | -183.38 | -378.99 | -586.82 |
Diluted Net EPS (GAAP) | -138.46 | -353.15 | -183.38 | -378.99 | -586.83 |
Fiscal Year end for NovaBay Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 2.63 | 3.73 | 3.27 | 4.61 |
Cost Of Goods | NA | 0.84 | 1.91 | 1.43 | 2.30 |
Gross Profit | NA | 1.79 | 1.81 | 1.84 | 2.31 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 4.23 | 5.20 | 2.95 | 3.66 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -2.44 | -3.39 | -1.11 | -1.35 |
Non-Operating Income | NA | -0.65 | -0.72 | -0.64 | -0.68 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -3.09 | -4.11 | -1.76 | -2.04 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -3.09 | -4.11 | -1.76 | -2.04 |
Extras & Discontinued Operations | NA | -0.12 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -3.21 | -4.11 | -1.76 | -2.04 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 0.71 | 0.20 | 0.13 | 0.09 |
Diluted EPS Before Non-Recurring Items | NA | -4.90 | -33.22 | -12.94 | -44.41 |
Diluted Net EPS (GAAP) | NA | -5.24 | -51.40 | -12.94 | -44.41 |